Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastro-enteropancreatic Neuroendocrine Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Not applicableStudy completedNCT01423734
What this trial is testing

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorSecondary Malignant Neoplasm of Liver
Memorial Sloan Kettering Cancer Center 20
Large-scale testing (Phase 3)Study completedNCT04852679
What this trial is testing

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 43
Testing effectiveness (Phase 2)Looking for participantsNCT05773274
What this trial is testing

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Who this might be right for
Metastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT04837885
What this trial is testing

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

Who this might be right for
Neuroendocrine TumorLiver MetastasesNeuroendocrine Gastroenteropancreatic Tumour
University Hospital, Bordeaux 23
Testing effectiveness (Phase 2)Study completedNCT03043664
What this trial is testing

Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Duke University 22
Not applicableStudy completedNCT06253897
What this trial is testing

Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorAcromegaly
Ipsen 20
Not applicableLooking for participantsNCT04090034
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsGastroenteropancreatic Neuroendocrine Tumor
Methodist Health System 50
Early research (Phase 1)Active Not RecruitingNCT04609592
What this trial is testing

Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Stanford University 10
Not applicableStudy completedNCT07653126
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany

Who this might be right for
Gastro-enteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 117
Early research (Phase 1)Study completedNCT01204476
What this trial is testing

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Who this might be right for
Gastrin-Producing Neuroendocrine TumorLung Carcinoid TumorMetastatic Digestive System Neuroendocrine Tumor G1+12 more
National Cancer Institute (NCI) 27
100